Clinical Trials Directory

Trials / Completed

CompletedNCT03475459

Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)

A Clinical Pharmacology Study of NPC-15 to Evaluate Arrhythmogenic Effect in Healthy Adults

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Nobelpharma · Industry
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

A study to assess the QTc prolongation effect of NPC-15 (melatonin 8mg or 16mg)

Detailed description

This study is a single center, open label, dose escalation trial to evaluate prolongation effect on QT interval of NPC-15 (melatonin 8mg or 16mg). The trial compose of 3 periods; During the each period, eligible volunteers wll be administered placebo, NPC-15 4g (melatonin 8mg) and NPC-15 8g(melatonin 16mg) as a sequential manner.

Conditions

Interventions

TypeNameDescription
DRUGNPC-15 and/or PlaceboThe dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)

Timeline

Start date
2018-04-03
Primary completion
2018-04-29
Completion
2018-04-29
First posted
2018-03-23
Last updated
2018-06-28

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03475459. Inclusion in this directory is not an endorsement.